(106 days)
The RTVue with Normative Database is an optical coherence tomography system indicated for the in vivo imaging and measurement of the retina, retinal nerve fiber layer, and optic disc as an aid in the diagnosis and management of retinal disease. The RTVue with Normative Database is also a quantitative tool for the comparison of retinal nerve fiber layer, and optic disc measurements in the human eye to a database of known normal subjects. It is intended for use as a diagnostic device to aid in the detection and management of ocular diseases.
The RTVue is a computer controlled ophthalmic imaging and measurement system that employs optical coherence tomography to image and measure the posterior segment of the eye. The device is currently cleared for in vivo imaging and measurement of the various retinal layers (K062552). Imaging and measurements include but are not limited to the internal limiting membrane (ILM), the retinal nerve fiber layer (RNFL), the ganglion cell complex (GCC), the retinal pigment epithelium (RPE), the outer retinal thickness, the total retinal thickness and optic disk structures including the cup and neuroretinal rim as an aid in the diagnosis and management of retinal disease. The measurements for the ILM and RPE are height measurements relative to the RPE reference plane. The RNFL. GCC. the outer retinal thickness and total retinal thickness measurements where RNFL is the thickness of the RNFL layer, the GCC is the thickness from the ILM to the inner plexiform layer (IPL), the outer retinal thickness is the thickness from the IPL to the RPE, and total retinal thickness is the thickness from the ILM to the RPE. The current submission is for a software modification to add a normative database. With the additional normative database (NDB), the RTVue can compare the measured data from the GCC, the RNFL, the full retinal thickness, optic disc cup and optic disc rim measurements to the normative database. The RTVue with Normative Database provides a statistical reference of the GCC, the RNFL, the full retinal thickness, optic disc cup and optic disc rim measurements to a database of known normal subjects. The RTVue with Normative Database will provide the analysis information to be used as a clinical reference to aid in the diagnosis and management of ocular diseases.
1. Acceptance Criteria and Reported Device Performance:
The document describes a precision study to evaluate the RTVue with Normative Database. The acceptance criteria are implicitly demonstrated by presenting the repeatability and reproducibility standard deviations for various measurements. The "Performance Data" section outlines these results.
The acceptance criteria are not explicitly stated, however based on the precision study results for repeatability and reproducibility, the device performance is within acceptable limits for a medical device.
Table of Performance Results
| Scan Type & Measurement | Patient Group | Repeatability SD (Min, Max) | Reproducibility SD (Min, Max) |
|---|---|---|---|
| EMM5 Scan Results | |||
| Full Retina Fovea | Normal Patients | 2.57 (1.66, 2.57) | 17.72 (1.66, 17.72) |
| Retina Patients | 2.96 (1.83, 3.15) | 13.78 (1.83, 13.78) | |
| Glaucoma Patients | 3.01 (1.95, 3.01) | 3.01 (2.05, 5.80) | |
| Full Retina Peripheral | Normal Patients | 1.96 (1.66, 2.57) | 2.01 (1.66, 17.72) |
| Retina Patients | 2.69 (1.83, 3.15) | 2.69 (1.83, 13.78) | |
| Glaucoma Patients | 2.35 (1.95, 3.01) | 2.66 (2.05, 5.80) | |
| ONH Scan Results | |||
| Average RNFL | Normal Patients | 1.76 (1.76, 6.18) | 2.11 (2.11, 9.78) |
| Glaucoma Patients | 1.56 (1.56, 5.86) | 7.87 (3.92, 16.33) | |
| RNFL Avg (2 Hemis, 4 Quads, 8 Sectors) | Normal Patients | 3.92 (1.76, 6.18) | 5.40 (2.11, 9.78) |
| Glaucoma Patients | 4.48 (1.56, 5.86) | 7.84 (3.92, 16.33) | |
| Cup Area | Normal Patients | 0.02 (0.02, 0.03) | 0.02 (0.02, 0.03) |
| Glaucoma Patients | 0.07 (0.07, 0.21) | 0.07 (0.07, 0.21) | |
| Rim Area | Normal Patients | 0.03 (0.02, 0.03) | 0.03 (0.02, 0.03) |
| Glaucoma Patients | 0.18 (0.07, 0.21) | 0.18 (0.07, 0.21) | |
| Vertical CD Ratio | Normal Patients | 0.01 (0.01, 0.04) | 0.01 (0.01, 0.04) |
| Glaucoma Patients | 0.05 (0.05, 0.08) | 0.05 (0.05, 0.08) | |
| GCC Scan Results | |||
| Inner Retina Average | Normal Patients | 1.86 (1.86, 2.07) | 7.56 (7.32, 7.92) |
| Glaucoma Patients | 1.18 (1.18, 1.59) | 2.55 (1.59, 3.36) | |
| GCC FLV | Normal Patients | 0.37 (0.37, 0.37) | 0.46 (0.46, 0.46) |
| Glaucoma Patients | 0.88 (0.88, 0.88) | 1.04 (1.04, 1.04) | |
| GCC GLV | Normal Patients | 0.83 (0.83, 0.83) | 2.44 (2.44, 2.44) |
| Glaucoma Patients | 1.03 (1.03, 1.03) | 1.71 (1.71, 1.71) |
2. Sample Size for Test Set and Data Provenance:
- Sample Size for Test Set: A total of 36 subjects were used in the precision study. This included 4 normal subjects, 4 retina patients, and 4 glaucoma patients for each of the 3 RTVue devices used (12 subjects per device).
- Data Provenance: The data was collected at two clinical sites. The document implies a prospective nature as subjects were "enrolled in the study," and "data was carefully reviewed for completeness and quality." The country of origin is not explicitly stated but can be inferred as the United States given the FDA submission.
3. Number of Experts and Qualifications for Ground Truth:
- Number of Experts: The ground truth for subject classification (normal, glaucoma, retina pathology) was established by the "Principal Investigator (PI) at each clinical site." The exact number of PIs is not specified but there were two clinical sites.
- Qualifications of Experts: The PIs diagnosed glaucoma and various retina pathologies. Their specific qualifications (e.g., "Radiologist with 10 years of experience") are not detailed beyond being a "Principal Investigator" responsible for diagnosis.
4. Adjudication Method:
The document mentions that all data was "carefully reviewed for completeness and quality in two levels," including a review of the CRF by the PI against inclusion/exclusion criteria, and a review of individual scans for image quality. There is no explicit mention of an adjudication method (like 2+1 or 3+1 consensus) for establishing the diagnostic ground truth for patient classification. The PI at each site made the diagnosis.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
No MRMC comparative effectiveness study is described. The study focuses on the precision (repeatability and reproducibility) of the RTVue device itself, not on the improvement of human readers with AI assistance. The additional normative database (NDB) functions as a reference tool for comparison rather than a direct AI-assisted diagnostic aid for human readers in the context of this study.
6. Standalone Performance:
Yes, a standalone performance study was done. The precision study evaluates the RTVue device (algorithm only, in the sense of its measurement capabilities and normative database comparison) without human interpretation as the primary outcome. The results presented are the repeatability and reproducibility of the device's measurements.
7. Type of Ground Truth Used:
The ground truth used for classifying subjects into normal, glaucoma, or retina pathology groups was expert consensus (diagnosis by the Principal Investigator).
8. Sample Size for Training Set:
The "Normative Databases" section states that normative data was collected from 480 individuals (over 640 eyes) for the database. This acts as the "training set" for the normative database comparison feature of the device.
9. How Ground Truth for Training Set was Established:
The ground truth for the normative database was established by enrolling "known healthy eyes" from these 480 individuals. This implies that subjects were deemed healthy based on a medical evaluation, likely conducted by qualified medical professionals at the 11 clinical sites following an IRB approved protocol. The criteria for "healthy eyes" would have been part of this protocol, but are not explicitly detailed in the document.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the word "optovue" in a stylized font. The "o" in "optovue" is replaced with an image of an eye. There is a curved line above the word "optovue".
1101505
510(k) Summary
Optovue, Inc. RTVue with Normative Database
SEP 1 5 2010
This 510(k) summary for the RTVue with Normative Database is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
General Information
| Manufacturer: | Optovue, Inc.45531 Northport Loop West,Fremont, CA 94538Phone: (510) 623-8868Fax: (510) 623-8668Registration No.: 3005950902 |
|---|---|
| Contact Person: | John TalaricoVP of Regulatory and Clinical AffairsOptovue, Inc.Phone: (510) 623-8868 x209e-mail: john_talarico@optovue.com |
| Device Information | |
| Classification: | Class II |
| Trade Name: | RTVue with Normative Database |
| Common Name: | Optical Coherence Tomography (OCT) |
| Classification Name: | Ophthalmoscope, a-c powered (21 CFR§ 886.1570) |
Predicate Device
- (1) RTVue with CA (K071250) -- Manufactured by Optovue, Inc.
- (2) StratusOCT with RNFL & Macula Normative Database (K033123) manufactured by Carl Zeiss Meditec, Inc.
Intended Use
The RTVue with Normative Database is an optical coherence tomography system indicated for the in-The NY Tue With Norman of the retina, retinal nerve fiber layer, and optic disc as an aid in the diagnosis and management of retinal disease. The RTVue with Normative Database is also a
{1}------------------------------------------------
quantitative tool for the comparison of retinal nerve fiber layer, and optic disc measurements in the human eye to a database of known normal subjects. It is intended for use as a diagnostic device to aid in the detection and management of ocular diseases.
Device Description
The RTVue is a computer controlled ophthalmic imaging and measurement system that employs optical coherence tomography to image and measure the posterior segment of the eye. The device is currently cleared for in vivo imaging and measurement of the various retinal layers (K062552). Imaging and measurements include but are not limited to the internal limiting membrane (ILM), the retinal nerve fiber layer (RNFL), the ganglion cell complex (GCC), the retinal pigment epithelium (RPE), the outer retinal thickness, the total retinal thickness and optic disk structures including the cup and neuroretinal rim as an aid in the diagnosis and management of retinal disease. The measurements for the ILM and RPE are height measurements relative to the RPE reference plane. The RNFL. GCC. the outer retinal thickness and total retinal thickness measurements where RNFL is the thickness of the RNFL layer, the GCC is the thickness from the ILM to the inner plexiform layer (IPL), the outer retinal thickness is the thickness from the IPL to the RPE, and total retinal thickness is the thickness from the ILM to the RPE. The current submission is for a software modification to add a normative database. With the additional normative database (NDB), the RTVue can compare the measured data from the GCC, the RNFL, the full retinal thickness, optic disc cup and optic disc rim measurements to the normative database. The RTVue with Normative Database provides a statistical reference of the GCC, the RNFL, the full retinal thickness, optic disc cup and optic disc rim measurements to a database of known normal subjects. The RTVue with Normative Database will provide the analysis information to be used as a clinical reference to aid in the diagnosis and management of ocular diseases.
Substantial Equivalence
The RTVue with Normative Database is substantially equivalent to the predicate device identified previously. The RTVue is similar to the previously cleared RTVue device with regard to intended use, operating principle, function, material, and energy source. Technological comparisons and clinical testing demonstrate that the RTVue with Normative Database is functionally equivalent to the predicate devices.
Performance Data
Clinical data was collected and evaluated to support the intended use for the RTVue with Normative Database and to demonstrate substantial equivalence to the predicate devices.
Description of Precision Study, Subject Selection Criteria and Pathologies
Instrument:
Three RTVue (K062552) with three different operators were used in this study. Measurements results of various structures within the eye including retinal thickness, optic disc measurements, and Ganglion Cell Complex (GCC) measurements were compared in normal eyes, and eyes with retina pathology and glaucoma.
Scans:
The RTVue device has three scan patterns where measurements are compared to a normative database. These scans include the 1) EMM5 scan, 2) the ONH scan, and 3) the GCC scan. The
{2}------------------------------------------------
EMM5 scan is centered on the fovea and provides measurements of the full retina thickness and the inner retina thickness. Only the full retina thickness measurements are compared to the normative database. This scan can be used to assess possible retina pathologies. The ONH scan is centered on the optic disc and provides measurements of the RNFL and optic disc. This scan can be used to assess possible glaucoma. The GCC scan is centered at 1 mm off from the fovea in order to cover more temporal retina area. It provides measurements of the inner retina layers that contain the ganglion cell axon (RNFL), cell body, and dendrite (inner plexiform layer). This scan can be used to assess glaucoma. Both eyes were scanned in each subject.
Subjects:
- Normal healthy eyes with no ocular pathology, 2) glaucoma patients and, 3) retina patients were enrolled in the study at two clinical sites. Normal subjects were from ocular pathology as determined by the Principal Investigator (PI) at each clinical site. Glaucoma patients were diagnosed as having glaucoma by the PI at each site. Retina patients included subjects with any type of retina pathology diagnosed by the PI. Retina pathologies included but were not limited to, AMD, DME, and ERM. There were 4 normal subjects, 4 retina patients, and 4 glaucoma patients enrolled for each RTVue devices. There were 3 RTVue devices at 2 clinical sites. At one site, there were 2 RTVues systems and 2 operators at different times. In total, there were 12 subjects enrolled for each of the 3 RTVue devices; a total of 36 subjects were used from the study.
Selection Criteria:
All data was carefully reviewed for completeness and quality in two levels, namely, the subject level and the individual scan level. At the subject level, the CRF was carefully reviewed to qualify each subject against all inclusion and exclusion criteria by comparing the study protocol with the CRF. At the individual scan level, the data was reviewed for quality to ensure data meeting inclusion criteria was accepted.
In a clinical environment, only scans with acceptable quality should be used. In order to match our analysis with acceptable clinical results, we reviewed and excluded all scans in the study with poor image quality. Image quality is based on a number of factors, including overall signal strength, localized weak signals, eye blink, data out of boundary, and data off-center. Due to the selection criteria, the sample size for each scan type varies.
Precision Results
The following tables provide the precision results for the scans with RTVue with Normative Database with both eyes combined. The data in the tables include the number of scans per subject group, the overall mean, the standard deviation, the repeatability standard deviation (median value of subfields with the minimum subfield value and the maximum subfield value), and reproducibility standard deviation (median value of subfields with the minimum subfield value and the maximum subfield value).
- EMM5 Scan Results (Normal and Retina Patients) i)
The following tables show the overall precision results with the EMM5 scan for full retinal thickness in the fovea for normals and retina patients.
| EMM5 | |||
|---|---|---|---|
| Full Retina Fovea | |||
| Normal Patients | Retina Patients | Glaucoma Patients |
{3}------------------------------------------------
| # of Scans | 71 | 71 | 71 |
|---|---|---|---|
| Overall Mean (Overall SD) | 243.61 (26.00) | 267.15 (73.32) | 246.22 (22.14) |
| Repeatability SD* (Min, Max) | 2.57(1.66, 2.57) | 2.96(1.83, 3.15) | 3.01(1.95, 3.01) |
| Reproducibility SD** (Min. Max) | 17.72(1.66, 17.72) | 13.78(1.83, 13.78) | 3.01(2.05, 5.80) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the EMM5 scan for full retinal thickness in the periphery (average over 8 sectors outside the fovea) for normals and retina patients.
| EMM5Full Retina Thickness Peripheral Results | |||
|---|---|---|---|
| Normal Patients | Retina Patients | Glaucoma Patients | |
| # of Scans | 71 | 71 | 71 |
| Overall Mean (Overall SD) | 295.05 (16.21) | 299.03 (30.70) | 282.30 (25.26) |
| Repeatability SD* (Min, Max) | 1.96(1.66, 2.57) | 2.69(1.83, 3.15) | 2.35(1.95, 3.01) |
| Reproducibility SD ** (Min, Max) | 2.01(1.66, 17.72) | 2.69(1.83, 13.78) | 2.66(2.05, 5.80) |
*estimate of the standard deviation among measurements taken on the same operator and device in the same testing session with repositioning.
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
ii) ONH Scan Results (Normals and Glaucoma Patients)
The following tables show the overall precision results with the ONH scan for average RNFL thickness for normals and glaucoma patients.
| ONHAverage RNFL | ||
|---|---|---|
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 72 |
| Overall Mean (Overall SD) | 100.82 (8.11) | 86.40 (14.99) |
| Repeatability SD* (Min, Max) | 1.76(1.76, 6.18) | 1.56(1.56, 5.86) |
| Reproducibility SD** (Min, Max) | 2.11(2.11, 9.78) | 7.87(3.92, 16.33) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the ONH scan for the average over 2 hemi-spheres, 4 quadrants, and 8 sectors for normals and glaucoma patients.
| ONH | ||
|---|---|---|
| RNFL averaged over 2 Hemispheres, 4 Quadrants, 8 Sectors | ||
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 72 |
| Overall Mean (Overall SD) | 100.82 (14.80) | 86.41 (18.55) |
{4}------------------------------------------------
| Optovue RTVue with NDB 510(K) Premarket Notification | ||
|---|---|---|
| ------------------------------------------------------ | -- | -- |
| Repeatability SD* (Min, Max) | 3.92(1.76, 6.18) | 4.48(1.56, 5.86) |
|---|---|---|
| Reproducibility SD** (Min, Max) | 5.40(2.11, 9.78) | 7.84(3.92, 16.33) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the ONH scan for the cup area measurement for normals and glaucoma patients.
| ONHCup Area | ||
|---|---|---|
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 72 |
| Overall Mean (Overall SD) | 0.39 (0.18) | 1.04 (0.53) |
| Repeatability SD* (Min, Max) | 0.02 (0.02, 0.03) | 0.07(0.07, 0.21) |
| Reproducibility SD** (Min, Max) | 0.02 (0.02, 0.03) | 0.07(0.07, 0.21) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
**estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the ONH scan for the rim area measurement for normals and glaucoma patients.
| ONH | ||
|---|---|---|
| Rim Area | ||
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 72 |
| Overall Mean (Overall SD) | 0.69 (0.17) | 0.89 (0.66) |
| Repeatability SD* (Min, Max) | 0.03 (0.02, 0.03) | 0.18(0.07, 0.21) |
| Reproducibility SD** (Min, Max) | 0.03 (0.02, 0.03) | 0.18(0.07, 0.21) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the ONH scan for the vertical CD ratio measurement for normals and glaucoma patients.
| ONHVertical CD Ratio | ||
|---|---|---|
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 72 |
| Overall Mean (Overall SD) | 2.15 (0.65) | 0.76 (0.23) |
| Repeatability SD* (Min, Max) | 0.01 (0.01, 0.04) | 0.05(0.05, 0.08) |
| Reproducibility SD** (Min, Max) | 0.01 (0.01, 0.04) | 0.05(0.05, 0.08) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
{5}------------------------------------------------
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
iii) GCC Scan Results (Normals and Glaucoma Patients)
The following tables show the overall precision results with the GCC scan for the inner retina average for normals and glaucoma patients.
| GCCInner Retina Average | ||
|---|---|---|
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 71 |
| Overall Mean (Overall SD) | 98.28 (9.31) | 81.76 (8.90) |
| Repeatability SD* (Min, Max) | 1.86 (1.86, 2.07) | 1.18 (1.18, 1.59) |
| Reproducibility SD ** (Min, Max) | 7.56 (7.32, 7.92) | 2.55 (1.59, 3.36) |
*estimate of the standard deviation among measurements taken on the same operator and device in the same testing session with repositioning.
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the GCC scan for the FLV thickness measurement for normals and glaucoma patients.
| GCCGCC FLV | ||
|---|---|---|
| Normal Patients | Glaucoma Patients | |
| # of Scans | 72 | 71 |
| Overall Mean (Overall SD) | 0.60 (0.67) | 4.30 (3.47) |
| Repeatability SD* (Min, Max) | 0.37 (0.37, 0.37) | 0.88 (0.88, 0.88) |
| Reproducibility SD** (Min, Max) | 0.46 (0.46, 0.46) | 1.04 (1.04, 1.04) |
*estimate of the standard deviation among measurements taken on the same operator and device in the same testing session with repositioning.
**estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
The following tables show the overall precision results with the GCC scan for the GLV thickness measurement for normals and glaucoma patients.
| GCCGCC GLV | |||||
|---|---|---|---|---|---|
| Normal Patients | Glaucoma Patients | ||||
| # of Scans | 72 | 71 | |||
| Overall Mean (Overall SD) | 3.99 (3.43) | 15.51 (7.81) | |||
| Repeatability SD* (Min, Max) | 0.83 (0.83, 0.83) | 1.03 (1.03, 1.03) | |||
| Reproducibility SD ** (Min, Max) | 2.44 (2.44, 2.44) | 1.71 (1.71, 1.71) |
*estimate of the standard deviation among measurements taken on the same subject using the same operator and device in the same testing session with repositioning.
{6}------------------------------------------------
** estimate of the standard deviation among measurements taken on different subjects using different operators and devices, including repeatability; in some cases the maximum reproducibility estimates were impacted by mean thickness difference between subjects in different sites.
Registration Results
Image registration using blood vessel matching is used for both the EMM5 scan and the ONH scan. The image registration algorithm uses a reference image to register all scans based on matching detected blood vessel patterns. For this internal validation study, we performed both an accuracy test as well as a precision test in order to evaluate the efficacy of the blood vessel registration method.
The following tables show the values at 2 times the standard deviation values for each parameters for these two scan types.
| EMM5 | FRT Fovea | FRT Para Tempo | FRT Para Superior | FRT Para Nasal | FRT Para Inferior | FRT Peri Tempo | FRT Peri Superior | FRT Peri Nasal | FRT Peri Inferior |
|---|---|---|---|---|---|---|---|---|---|
| 6.345 | 3.9121 | 4.6186 | 3.6347 | 2.795 | 5.568 | 5.669 | 4.772 | 3.63 |
| റപ്പ് | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------י זיח | am------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | CL T | No. one possible from the mayS. YO Y | די | 61 | The first of the county of1 | |
|---|---|---|---|---|---|---|---|---|
| 0 | e | € | ---------1----------------- | C | S0.0 |
Normative Databases
The normative data was collected at 11 clinical sites following an IRB approved protocol and enrolled known healthy eyes from 480 individuals (over 640 eyes) with a wide age range (18-84) from various ethnic backgrounds including 33% Caucasians, 22% Asians, 20% African Americans, 12% Hispanics, 12% Indian, and 1% other, approximately. Normative databases are adjusted by age, signal strength and disc area (where applicable), not by axial length, refraction or any other parameters. The normative limits do not take into account differences that may be present due to ethnicity.
In our clinical studies, the repeatability and reproducibility were found to be very good and were found to be similar for normal groups and pathology groups. We believe the Normative Database is a good representation of the patient population because it was created from a large population of patients from 11 clinical sites worldwide. Ocular measurements taken by the RTVue have been compared to other OCT devices by renowned leaders in the field of Ophthalmology and found to have good repeatability and reproducibility 1-5.
Conclusion
As described in this 510(k) Summary, all testing and analysis were completed on the RTVue with Normative Database to ensure that the device is safe and effective for its intended.
Tan O, Chopra V, Lu A, Schunan J, Ishkawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier l. Domain Optical Coherence Tomography. Ophthalmol. 2009; 116:2305-2314.
Donall Optical Collection Touristic 2007, 10:230, 10.230, 10.230, 10.12 Reproducibility of RTVer Layer Thickness 2. Optic Disc Measurements and Agreement with Straus Optical Coherence Tomography Measurements. Am J Ophthalment (1909 Mar 5
Opic Disc Measurements and Agreement Will Suatts Optical Contractions Frin Opiliations Print of Partin Province Province Printer Price Printer Print Province Price Portugio 3. tomography. Ophthalmol. 2010; 117: 738-746.
toniolality. Ophilimino. 2000, 11:17 Comparison of repeatability of retinal nerve fiber thickness measurement made with the RT 4. domain Optocal Collerence Tomograph and the GDx Scanning Laser Polarimeter with Variable or Enhanced Comea Compensation. J Glaucoma. Oct
Sehi M, Grewal DS, Sheets CW, Greenfield DS. Diagnostic ability of Fourier-domain optical coherence tomography for glaus 5. detection. Am J Ophthalmol. 2009; 148: 597-605.
{7}------------------------------------------------
Image /page/7/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight, composed of three stylized, curved lines.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Optovue, Inc c/o Mr. John Talarico VP Regulatory and Clinical Affairs 45531 Northport Loop W. Fremont, CA 94538
SEP 1 5 2010
Re: K101505
Trade/Device Name: RTVue with Normative Database Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Code: HLI Dated: August 12, 2010 Received: August 19, 2010
Dear Mr. Talarico:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
{8}------------------------------------------------
Page 2 - Mr. John Talarico
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Kevia Alexander
Malvina B. Eydelman, M.D. Director
Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{9}------------------------------------------------
Indications for Use
KI0ISOS
510(k) Number (if known):
SEP 1 5 2010
Device Name: RTVue with Normative Database
Indications For Use:
The RTVue with Normative Database is an optical coherence tomography system indicated for the in vivo imaging and measurement of the retinal nerve fiber layer, and optic disk as an aid in the diagnosis and management of retinal disease. The RTVue with Normative Database is also a quantitative tool for the comparison of retina, retinal nerve fiber layer, and optic disk measurements in the human eye to a database of known normal subjects. It is intended for use as a diagnostic device to aid in the detection and management of ocular diseases.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Sesn.
(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices
510(k) Number K101505 Page 18 of 922
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.